Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.

Autor:	Janssen, Q. P.1 (AUTHOR), van Dam, J. L.1 (AUTHOR), Bonsing, B. A.2 (AUTHOR), Bos, H.3 (AUTHOR), Bosscha, K. P.4 (AUTHOR), Coene, P. P. L. O.5 (AUTHOR), van Eijck, C. H. J.1 (AUTHOR), de Hingh, I. H. J. T.6 (AUTHOR), Karsten, T. M.7 (AUTHOR), van der Kolk, M. B.8 (AUTHOR), Patijn, G. A.9 (AUTHOR), Liem, M. S. L.10 (AUTHOR), van Santvoort, H. C.11 (AUTHOR), Loosveld, O. J. L.12 (AUTHOR), de Vos-Geelen, J.13 (AUTHOR), Zonderhuis, B. M.14 (AUTHOR), Homs, M. Y. V.15 (AUTHOR), van Tienhoven, G.16 (AUTHOR), Besselink, M. G.17 (AUTHOR), Wilmink, J. W.18 (AUTHOR)
Zdroj:	BMC Cancer. 3/23/2021, Vol. 21 Issue 1, p1-8. 8p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu